INDUSTRY NEWS - CAR-T in autoimmunity
My thoughts on the news 'Cartesian Therapeutics clears an autoimmune CAR-T trial, starts another Phase 2 and raises $130M' https://lnkd.in/eHtpW7T3
This is an exciting development that expands on tantalizing CAR-T data in autoimmunity first reported in lupus last year.
Is autoimmunity the saving grace for the CAR-T field as multiple companies migrate from oncology?
The competition will be no less fierce in autoimmunity where mAbs have made significant advances over the years and are truly off-the-shelf products, and cheaper as well.
One key question concerns how many CAR-T products can the autoimmunity field accommodate, especially if they are all targeting B cell specific antigens. Perhaps the competitive landscape will be adjudicated by the relative durability of any response.
Whereas the durability of mAb function is dictated by standard pharmacokinetics, the durability of CAR-T responses may be longer if they function as an immunomodulatory reset to the immune system.
Time and data will tell.
#Alloplex #celltherapies #CAR-T #oncologyresearch #cancerresearch
Senior Director, Assay Development and Quality Control at Abeona Therapeutics
3moSo proud to be part of this team! And serving these incredible patients!